In the phase I/II CHORUS trial, adding the IL-1β inhibitor canakinumab to concurrent chemoradiotherapy and consolidative durvalumab produced favorable progression-free survival outcomes in unresectable stage III non-small cell lung cancer. With a reported 24-month PFS rate of 67%, the results suggest a possible immunomodulatory path to improve durability beyond standard chemoradiation plus PD-L1 blockade. The trial design links cytokine blockade to the tumor microenvironment reshaped by chemoradiotherapy, reflecting growing interest in combining innate immune signaling modulation with checkpoint therapy. For clinicians, PFS is especially relevant in stage III disease because it informs next-step treatment strategies and trial eligibility for additional intensification. While early-phase findings are not definitive for labeling, they can influence the design of later confirmatory programs. Safety and tolerability profiles will remain a central factor in determining whether the regimen can be scaled. For the broader thoracic oncology pipeline, CHORUS strengthens the rationale for IL-1β-targeted strategies as add-ons to CRT and durvalumab in selected patients.